US 11,667,639 B2
Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
Michael P. Lisanti, Fulton, MD (US); and Federica Sotgia, Fulton, MD (US)
Assigned to LUNELLA BIOTECH, INC., Ontario (CA)
Appl. No. 16/626,426
Filed by LUNELLA BIOTECH, INC., Ottawa (CA)
PCT Filed Jun. 25, 2018, PCT No. PCT/US2018/039394
§ 371(c)(1), (2) Date Dec. 24, 2019,
PCT Pub. No. WO2019/005698, PCT Pub. Date Feb. 3, 2019.
Claims priority of provisional application 62/524,829, filed on Jun. 26, 2017.
Prior Publication US 2020/0148688 A1, May 14, 2020
Int. Cl. C07D 487/04 (2006.01); C07D 209/42 (2006.01); G16C 20/50 (2019.01); C07D 265/36 (2006.01); C07D 417/12 (2006.01); C40B 30/06 (2006.01); C40B 40/14 (2006.01)
CPC C07D 487/04 (2013.01) [C07D 209/42 (2013.01); C07D 265/36 (2013.01); C07D 417/12 (2013.01); C40B 30/06 (2013.01); C40B 40/14 (2013.01); G16C 20/50 (2019.02)] 7 Claims
 
1. A pharmaceutical composition comprising, as an active ingredient, a compound having the general formula:

OG Complex Work Unit Chemistry
wherein each R may be the same or different and is selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, carboxyl, alkanes, cyclic alkanes, alkenes, cyclic alkenes, alkynes, ketones, aldehydes, carboxylic acids, ethers, esters, amines, amides, monocyclic or polycyclic arene, heteroarenes, phenols, and benzoic acid; and
a pharmaceutically acceptable carrier or excipient;
wherein the concentration of the active ingredient is sufficient to inhibit the formation of MCF7 mammospheres in a human tumor; and
wherein the pharmaceutical composition is in a form selected from the group comprising a tablet, a pill, a powder, and a capsule.